Yamagami T, Shibata N, Folkers K
Res Commun Chem Pathol Pharmacol. 1976 Aug;14(4):721-7.
Coenzyme Q10 has been administered to five patients having essential hypertension and deficiencies of activity of succinate dehydrogenase-co-enzyme Q10 reductase in leucocyte preparations ranging from 20-40%. For a 74-year old male, the systolic pressure was reduced (p less than 0.001), the diastolic pressure was reduced (p less than 0.05), the specific activity of the coenzyme Q10-enzyme was increased (p less than 0.001), and the deficiency of coenzyme Q10 activity was negated (p less than 0.01). Four patients receiving CoQ10 for 3-5 months showed reductions (p less than 0.05 to p less than 0.001) of diastolic pressure, and 3 of these 4 showed reductions (p less than 0.05 to p less than 0.01) of diastolic pressure. Initial deficiencies of enzyme activity were reduced (p less than 0.01 to 0.05) in two patients. Three other patients did not show the high level of deficiency on treatment as initially observed. These effects of CoQ10 on the reduction of systolic and diastolic blood pressures, increase in CoQ10-enzyme activity, and reduction of CoQ10-deficiency are presumably due to improved bioenergetics through correction of a deficiency of coenzyme Q10.
已对5例原发性高血压患者给予辅酶Q10，这些患者白细胞制剂中琥珀酸脱氢酶 - 辅酶Q10还原酶活性缺乏，缺乏程度在20%至40%之间。对于一名74岁男性患者，收缩压降低（p<0.001），舒张压降低（p<0.05），辅酶Q10 - 酶的比活性增加（p<0.001），辅酶Q10活性缺乏得到纠正（p<0.01）。4例接受辅酶Q10治疗3至5个月的患者舒张压降低（p<0.05至p<0.001），其中3例收缩压降低（p<0.05至p<0.01）。2例患者最初的酶活性缺乏有所减轻（p<0.01至0.05）。另外3例患者在治疗时未表现出最初观察到的高度缺乏情况。辅酶Q10对收缩压和舒张压降低、辅酶Q10 - 酶活性增加以及辅酶Q10缺乏减轻的这些作用，可能是由于通过纠正辅酶Q10缺乏改善了生物能量学。
